Dolores J. Schendel
Chief Tech/Sci/R&D Officer at MEDIGENE AG
Net worth: 2 M $ as of 30/03/2024
Profile
Dolores J.
Schendel is the founder of Medigene Immunotherapies GmbH, which was founded in 2014.
She held the title of Managing Director at the company.
Currently, Dr. Schendel is the Chief Executive Officer at Medigene, Inc. and the Chief Scientific Officer at MediGene AG, both of which she joined in 2014.
In her former positions, she was the Director at the Institute of Molecular Immunology from 1998 to 2013.
She also served as a Professor at Ludwig-Maximilians-Universität München and as a Member-Scientific Review Board at the European Research Council, Deutsche Forschungsgemeinschaft, and German Cancer Aid.
Dr. Schendel obtained her doctorate degree from the University of Wisconsin.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
MEDIGENE AG
3.45% | 29/06/2023 | 846,296 ( 3.45% ) | 2 M $ | 30/03/2024 |
Dolores J. Schendel active positions
| Companies | Position | Start |
|---|---|---|
| MEDIGENE AG | Chief Tech/Sci/R&D Officer | 30/04/2014 |
MediGene, Inc.
 MediGene, Inc. Pharmaceuticals: MajorHealth Technology MediGene, Inc. develops herpes simplex virus technologies for the treatment of tumors and for gene delivery. The company was founded by Ram Bhatt and Frank Tufaro and is headquartered in San Diego, CA. | Chief Executive Officer | - |
Former positions of Dolores J. Schendel
| Companies | Position | End |
|---|---|---|
| Institute of Molecular Immunology | Director/Board Member | 31/12/2012 |
European Research Council
 European Research Council Investment Trusts/Mutual FundsMiscellaneous The European Research Council is an organization that provides grants for research projects. The organization is based in Brussels, Belgium. As a grantee, individuals are required to submit scientific and financial reports for assessment by ERC Scientific Officers. The organization emphasizes the importance of research ethics and compliance with legislation, disciplinary norms, and protection of research subjects. The responsibility for ethics lies with the individuals conducting the research, while the formal accountability lies with the signatory of the Grant Agreement, the Host Institution. | Corporate Officer/Principal | - |
| German Cancer Aid | Corporate Officer/Principal | - |
| Deutsche Forschungsgemeinschaft | Corporate Officer/Principal | - |
Medigene Immunotherapies GmbH
 Medigene Immunotherapies GmbH Pharmaceuticals: MajorHealth Technology Part of MediGene AG, Medigene Immunotherapies GmbH develops immunotherapy to treat cancer. The private company is based in Planegg, Germany. The German company was founded in 2013 by Thomas Blankenstein, Dolores J. Schendel. The CEO is Axel-Sven Malkomes. Medigene Immunotherapies was acquired by MediGene AG on January 27, 2014 for $13.05 million. | Chief Executive Officer | - |
Training of Dolores J. Schendel
| University of Wisconsin | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| MEDIGENE AG | Health Technology |
| Private companies | 5 |
|---|---|
MediGene, Inc.
MediGene, Inc. Pharmaceuticals: MajorHealth Technology MediGene, Inc. develops herpes simplex virus technologies for the treatment of tumors and for gene delivery. The company was founded by Ram Bhatt and Frank Tufaro and is headquartered in San Diego, CA. | Health Technology |
European Research Council
European Research Council Investment Trusts/Mutual FundsMiscellaneous The European Research Council is an organization that provides grants for research projects. The organization is based in Brussels, Belgium. As a grantee, individuals are required to submit scientific and financial reports for assessment by ERC Scientific Officers. The organization emphasizes the importance of research ethics and compliance with legislation, disciplinary norms, and protection of research subjects. The responsibility for ethics lies with the individuals conducting the research, while the formal accountability lies with the signatory of the Grant Agreement, the Host Institution. | Miscellaneous |
| Institute of Molecular Immunology | |
Medigene Immunotherapies GmbH
Medigene Immunotherapies GmbH Pharmaceuticals: MajorHealth Technology Part of MediGene AG, Medigene Immunotherapies GmbH develops immunotherapy to treat cancer. The private company is based in Planegg, Germany. The German company was founded in 2013 by Thomas Blankenstein, Dolores J. Schendel. The CEO is Axel-Sven Malkomes. Medigene Immunotherapies was acquired by MediGene AG on January 27, 2014 for $13.05 million. | Health Technology |
| German Cancer Aid |
- Stock Market
- Insiders
- Dolores J. Schendel
